When Aerovance Inc. decided last year to put off partnering plans for its Aerovant inhaled asthma program until after Phase IIb - with the goal of building up value for a better deal - the firm could not foresee the market's stunning decline in the latter part of 2008 that would make raising venture capital money a challenging prospect. (BioWorld Today) Read More
